• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

• 페이스북 공유
• 트위터 공유
• 

Personalized Postnatal Depression treatment Treatment

For a lot of people suffering from depression, traditional therapy and medication are ineffective. The individual approach to treatment could be the answer.

Cue is an intervention platform that transforms sensor data collected from smartphones into personalized micro-interventions to improve mental health. We analyzed the best-fitting personalized ML models for each individual, using Shapley values, in order to understand their characteristic predictors. The results revealed distinct characteristics that were deterministically changing mood over time.

Predictors of Mood

Depression is one of the world's leading causes of mental illness.1 Yet, only half of those who have the disorder receive treatment1. In order to improve outcomes, healthcare professionals must be able to recognize and treat patients who have the highest chance of responding to certain treatments.

Personalized depression treatment is one method to achieve this. Researchers at the University of Illinois Chicago are developing new methods to predict which patients will gain the most from certain treatments. They make use of sensors for mobile phones as well as a voice assistant that incorporates artificial intelligence as well as other digital tools. Two grants were awarded that total more than $10 million, they will employ these technologies to identify biological and behavioral predictors of responses to antidepressant medications as well as psychotherapy.

To date, the majority of research on factors that predict depression treatment effectiveness has been focused on the sociodemographic and clinical aspects. These include demographics such as gender, age, and education, and clinical characteristics like severity of symptom and comorbidities, as well as biological markers.

While many of these factors can be predicted by the information available in medical records, few studies have used longitudinal data to explore the causes of mood among individuals. A few studies also take into consideration the fact that moods can differ significantly between individuals. Therefore, it is important to develop methods that allow for the determination and quantification of the individual differences in mood predictors treatments, mood predictors, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team can then develop algorithms to recognize patterns of behaviour and emotions that are unique to each individual.

In addition to these modalities the team also developed a machine-learning algorithm that models the dynamic variables that influence each person's mood. The algorithm blends the individual differences to create a unique "digital genotype" for each participant.

This digital phenotype was correlated with CAT-DI scores, a psychometrically validated severity scale for symptom severity. However, the correlation was weak (Pearson's r = 0.08, BH-adjusted P-value of 3.55 1003) and varied widely across individuals.

Predictors of symptoms

Depression is one of the most prevalent causes of disability1 yet it is often not properly diagnosed and treated. In addition, a lack of effective treatments and stigmatization associated with depression treatments near me disorders hinder many people from seeking help.

To facilitate personalized treatment to improve treatment, identifying the predictors of symptoms is important. However, current prediction methods rely on clinical interview, which is not reliable and only detects a limited number of features related to depression.2

Machine learning is used to combine continuous digital behavioral phenotypes captured by sensors on smartphones and a validated online mental health tracker (the Computerized Adaptive Testing Depression Inventory, CAT-DI) together with other predictors of severity of symptoms has the potential to improve diagnostic accuracy and increase the effectiveness of treatment for depression. These digital phenotypes are able to capture a variety of distinct behaviors and activities that are difficult to record through interviews, and allow for continuous and high-resolution measurements.

The study involved University of California Los Angeles students who had mild to severe depression symptoms who were taking part in the Screening and Treatment for Anxiety and depression treatment food program29, which was developed as part of the UCLA Depression Grand Challenge. Participants were routed to online support or in-person clinical treatment in accordance with their severity of depression. Those with a score on the CAT-DI scale of 35 65 were assigned online support with an online peer coach, whereas those with a score of 75 were sent to in-person clinical care for psychotherapy.

Participants were asked a set of questions at the beginning of the study regarding their demographics and psychosocial characteristics. The questions covered age, sex, and education as well as marital status, financial status, whether they were divorced or not, the frequency of suicidal thoughts, intentions or attempts, as well as how often they drank. The CAT-DI was used for assessing the severity of depression symptoms on a scale of 0-100. The CAT-DI test was carried out every two weeks for those who received online support, and weekly for those who received in-person support.

Predictors of Treatment Reaction

Research is focused on individualized treatment for depression. Many studies are focused on finding predictors that can help doctors determine the most effective medications to treat each individual. Particularly, pharmacogenetics can identify genetic variants that influence the way that the body processes antidepressants. This lets doctors choose the medications that are most likely to work for each patient, reducing the amount of time and effort required for trial-and error treatments and avoid any negative side consequences.

Another promising approach is building models of prediction using a variety of data sources, such as the clinical information with neural imaging data. These models can be used to identify the most effective combination of variables that is predictive of a particular outcome, such as whether or not a drug will improve the mood and symptoms. These models can be used to determine the response of a patient to treatment, allowing doctors maximize the effectiveness.

A new type of research utilizes machine learning techniques such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to blend the effects of several variables to improve predictive accuracy. These models have been shown to be effective in predicting outcomes of treatment, such as response to antidepressants. These approaches are gaining popularity in psychiatry and it is likely that they will become the standard for the future of clinical practice.

The study of depression's underlying mechanisms continues, as well as ML-based predictive models. Recent research suggests that the disorder is linked with neural dysfunctions that affect specific circuits. This suggests that the treatment for depression will be individualized focused on therapies that target these circuits to restore normal functioning.

One method to achieve this is by using internet-based programs that can provide a more individualized and personalized experience for patients. For instance, one study discovered that a web-based treatment was more effective than standard care in reducing symptoms and ensuring a better quality of life for patients suffering from MDD. A controlled, randomized study of a customized treatment for depression showed that a significant percentage of participants experienced sustained improvement and had fewer adverse consequences.

Predictors of Side Effects

In the treatment of depression a major challenge is predicting and identifying the antidepressant that will cause very little or no adverse effects. Many patients are prescribed various medications before settling on a treatment that is safe and effective. Pharmacogenetics provides a novel and exciting way to select antidepressant drugs that are more efficient and targeted.

There are several predictors that can be used to determine the antidepressant to be prescribed, including gene variations, phenotypes of the patient such as gender or ethnicity and comorbidities. To determine the most reliable and valid predictors for a specific treatment, random controlled trials with larger numbers of participants will be required. This is because it could be more difficult to determine interactions or moderators in trials that contain only one episode per person instead of multiple episodes spread over a long period of time.

Additionally, the estimation of a patient's response to a specific medication will also likely require information on symptoms and comorbidities and the patient's previous experiences with the effectiveness and tolerability of the medication. There are currently only a few easily measurable sociodemographic variables as well as clinical variables appear to be reliably related to response to MDD. These include age, gender and race/ethnicity as well as BMI, SES and the presence of alexithymia.

Many challenges remain in the application of pharmacogenetics to treat depression. First, a clear understanding of the underlying genetic mechanisms is required and a clear definition of what constitutes a reliable predictor for psychological treatment for depression response. In addition, ethical concerns such as privacy and the ethical use of personal genetic information, should be considered with care. In the long run pharmacogenetics can offer a chance to lessen the stigma associated with mental health care and improve treatment outcomes for those struggling with depression. But, like any other psychiatric treatment, careful consideration and planning is necessary. At present, it's ideal to offer patients various depression medications that are effective and urge them to speak openly with their doctors.